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ABSTRACT 
 
Background: Depression is one of the most important causes of disability-adjusted life years. Currently, the majority of 
patients are treated with SSRIs. However, the effectiveness of SSRIs is questionable. Method: The purpose of this study 
was to determine the effectiveness of the pharmacotherapy treatment selective serotonin reuptake inhibitors (SSRIs) in 
patients diagnosed with major depression. This was achieved by comparison to other methods of antidepressant treatment 
such as, selective serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), electroconvulsive 
therapy (ECT), and psychotherapy. Results: The majority of patients were taking SSRIs for treatment of depression alone 
or in combination with other antidepressant medications. More than half those patients showed pharmacological 
effectiveness. However, patients who were taking other types of antidepressants also experienced reduction in their 
symptoms. Conclusion: The analysis of data that was collected from an outpatient mental health private practice, showed 
no advantage in effectiveness of SSRIs compared with other treatment options. 
 
Keywords: Selective serotonin reuptake inhibitors, SSRI, antidepressant, treatment of depression, selective serotonin 
norepinephrine reuptake inhibitors, SNRI, tricyclic antidepressants, TCA.
INTRODUCTION 
 
Depression is classified as a disability that impacts 
the daily life of a large number of peo-ple world-
wide. Specifically, “depression is the second leading 
cause of life years spent with dis-ability, and the 
third leading cause of disability-adjusted life 
years”.[1] Between 1990 and 1998 there was a 
147.5% increase in the number of patients diagnosed 
with depression.[2] Data from another study showed 
that between 2009-2012 at least 5% of Americans 12 
years of age and older had depression.[3] 
The anatomy and physiology behind depression is 
known to be an imbalance of emotional homeostasis 
in the limbic system, specifically between the 
prefrontal cortex, cingulate cortex, and amygdala4. 
The imbalance has to do mainly with serotonin, a 
neurotransmitter that plays a role in “the control of 
sleep and wakefulness, feeding, termoregulation, 
cardiovascular function, eme-sis, sexual behavior, 
spinal regulation of motor function, emotional and  
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psychotic behavior, and drug-induced hallucinatory 
states”.[5] Depression presents unusually low 
concentration levels of serotonin in the extracellular 
synapses of the brain. Although it is impossible to 
measure the actu-al level of   serotonin   in   a   living 
human due to the invasiveness of the procedure, 
neuroimaging techniques have been used to visualize 
major differences before and after treatments of 
interest6. To counteract this imbalance, 
antidepressant medications have been engineered to 
bind to one or more of the following monoamine 
transporter proteins: The serotonin transporter 
(SERT), the noradrenaline transporter (NAT), and 
the dopamine transporter (DAT).[1] By the 
monoamine transporters binding to the medication, 
there is a conformational change to inhibit the 
binding of the neurotransmitters.[1] The 
antidepressant medications are grouped into 
categories based on which monoamine transporter 
proteins they bind, such as: Tricyclic antidepressants 
and related compounds, dopamine-reuptake blocking 
compounds, 5-HT2 receptor antagonist properties, 5-
HT3 receptor antagonist properties, noradrenergic 
antagonist, monoamine oxidase inhibitors, sero-
tonin/norepinephrine reuptake inhibitors (SNRIs) 
and selective serotonin reuptake inhibitors 
(SSRIs).[7] Due to the high risk of side effects and 
lack of effectiveness or remission however, many 
patients are reluctant to take majority of 
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antidepressant medications and a total of 72% of 
patients discontinue taking the medications by the 
end of 3 months from first date prescribed.[8.,9] 
This study was carried out because depression is a 
serious public health concern world-wide.[10] The 
number of individuals receiving antidepressant 
pharmacologic treatments has in-creased. Yet, 
recently there has been found a statistically 
significant decrease in the rate of effec-tive 
treatments.[11] Today, the leading method of 
antidepressant treatment is the selective seroto-nin 
reuptake inhibitors (SSRIs).[12] The purpose of this 
study was to determine the effectiveness of SSRIs 
compared with other antidepressant medications. In 
this study, we hypothesized that SSRIs do not have 
significance over the effectiveness of other methods 
of antidepressant treat-ments. 
 
MATERIALS AND METHODS 
 
Fifty patients’ charts from an outpatient mental 
health private practice were randomly se-lected. The 
data from those charts were collected and analyzed. 
Since the files come from an outpatient mental 
health private practice, the patients were taking 
combination therapy of phar-macotherapy and 
psychotherapy. The determination of treatment 
effectiveness was based upon the reduction of 
symptoms and fewer side effects. 
 
RESULTS  
 
Thirty-four patients were female (68%) and the rest 
were male (32%). The age of patients ranged from 
20 to 81 years. As expected, the most common 
antidepressant prescribed was SSRIs. Of the 50 
patient files analyzed, a total of 88% individuals 
were medicating with one or more SSRIs, 16% were 
prescribed one or more SNRIs, 10% were prescribed 
one or more TCAs, and 40% were prescribed one or 
more of unrelated antidepressants. Such unrelated 
antidepres-sants are of the following: 5HTP, 
Trazodone, Wellbutrin XL, Wellbutrin XR, 
Remeron, Brintel-lix, and St. Johns Wort. Along 
with the antidepressant drugs being prescribed, other 
medications were listed for each patient.  
Medications prescribed to treat anxiety are of the 
following: Vistaril, Xanax, Klonopin, Buspirone, 
and Ativan. Medications prescribed that work as a 
central nervous system stimulant were: Ritalin, 
Concerta, Adderall XR, Provigil, Focalin, and 
Focalin XR. Antipsychotic drugs prescribed to the 
patients were: Abilify, Risperidone, and Seroquel. 
A total of 31 patients experienced pharmacologic 
effectiveness against depression with no side effects. 
Of the 50 total patients, 11 were prescribed one 
SSRI, and 8 of the 11 showed progress. Of the 50 
total patients, 33 were prescribed a combination of 
antidepressants that in-cluded at least one SSRI, and 
20 showed progress. 
Four patients were prescribed a single SNRI and 
another 4 patients were prescribed a combination of 
antidepressants including at least 1 SNRI. Of the 8 
patients prescribed one or more SNRI, a total of 5 
showed progress. Three of the 5 patients were 
prescribed one SNRI as the antidepressant, 1 patient 
took an SNRI in combination with Trazodone 
(antidepressant), and 1 patient was on SNRI in 
combination with Lexapro (SSRI). 
Of the 5 patients prescribed one or more TCA, 4 
showed progress. All 5 were taking a TCA in 
combination with other antidepressants, and no 
SNRIs or SSRIs. 
Of the 20 patients prescribed alternative 
antidepressant drugs, 14 showed progress. Nine-teen 
of the patients were taking at least one antidepressant 
in combination with other antidepres-sants 
(including SSRIs and SNRIs), 1 of the patients was 
taking an unrelated antidepressant alone. Of the 14 
patients that showed progress: 1 was taking the drug 
alone, 12 were taking the drug with a combination of 
other antidepressants, and 1 was taking the drug in 
combination with an SNRI. 
 
DISCUSSION 
 
The objective of this study was to determine the 
overall effectiveness of selective seroto-nin reuptake 
inhibitors in comparison to other methods of 
treatment for depression. Of all of the patients who 
were prescribed one SSRI or a combination 
containing at least one SSRI, 64% showed 
effectiveness. When analyzing the 64% of patient 
files, 88% of the files included pa-tients who were 
prescribed at least one SSRI. Of those 88%, 29% of 
patients were prescribed a single SSRI and 71% of 
patients were taking a combination including at least 
one SSRI. 
Of all of the patients who were prescribed one SNRI 
or a combination containing at least one SSRI, 63% 
showed effectiveness. Of those 63%, 36% of the 
patients were prescribed a single SNRI, and 27% of 
them were prescribed a combination containing at 
least one SNRI. When comparing patients who were 
taking SSRIs and SNRIs, the percentages of those 
who saw pro-gress are 64% and 63%, respectively. 
Patients who were taking TCA, 80% showed 
progress, and all of those patients were tak-ing a 
combination of antidepressants including at least one 
TCA. In comparing SSRIs and TCAs, the 
percentages of those who saw progress are 64% and 
80%, respectively. 
Seventy percent of patients prescribed 
antidepressants of unrelated classifications showed 
pro-gress. Five percent of the 70% were prescribed a 
single antidepressant and the remaining 65% of 
patients were prescribed a combination of 
antidepressants, at least one from an unrelated 
classifi-cation. In comparing SSRIs and unrelated 
antidepressant classifications, the percentages of 
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those who saw progress are 64% and 70%, 
respectively. 
T-tests were completed in the comparison of SSRIs 
and SNRIs, SSRIs and TCAs, and SSRIs and 
unrelated antidepressant classifications. The T-tests 
were two-tailed and the signifi-cance level was set at 
0.05.  
 
• SSRI vs SNRI: Z-score = 0.0614, p-value = 0.95216 
• SSRI vs TCA: Z-score = - 0.7284, p-value = 0.4654 
• SSRI vs unrelated antidepressants: Z-score = - 
0.4968, p-value = 0.61708 
All T-tests resulted in no statistical significance. 
However, 88% of the total patient files observed 
were prescribed one or more SSRI. Therefore, when 
analyzing data there are limitations on the 
conclusion of statistical significance of effectiveness 
as there are not as many patients with the remaining 
classifications of antidepressants. To eliminate the 
limitation, an additional T-test was calculated in the 
comparison of SSRIs and all other pharmacologic 
methods of treatment observed. The test was two-
tailed and the significance level was set at 0.05. The 
z-score was -0.5565 and the p-value was 0.57548. 
Again, the results yielded no statistical significance. 
There-fore, SSRIs are not significantly more 
effective than other methods of treatment. The 
details of the calculations for different groups are 
written below: 
 
CONCLUSION 
 
The objective of this study was to determine the 
overall rate of effectiveness of SSRIs in comparison 
to other pharmacologic methods of antidepressant 
treatments. The alternative treat-ments were SNRIs, 
TCAs, and a variety of antidepressants that did not 
fall into the related clas-sifications. Overall the study 
showed that SSRIs do not show a higher effectivity 
than other methods of antidepressant treatment. 
Although the overall rate of effectiveness is 72%, the 
rate could be significantly higher if SSRIs were not 
the first choice of treatment. However, the data for 
this study was drawn from an outpatient clinic with 
mostly Caucasian ethnicity. Further stud-ies with 
larger sample size, and patients with different ethnic 
background is needed. 
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